700 patients109,892 observations180 daysLIVE

Patient P-02634

Synthetic patientMETA-24 · Day 105 · 25–34 · M · baseline S14Steering view · 3DOpen companion preview
Is the drug working?

Metabolic response 75 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 54%, metabolic response 62 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 71 (resting HR +4 bpm, inflammatory load +10); the side effect would have been reported on day 96 — 25 days of warning.

Still taking it?

46 of 61 scheduled doses in the last 60 days are biologically confirmed (75%); 11 were logged but show no dose signature. Dose signature: resting HR +6 bpm, HRV −6 ms.

last 10 doses · green confirmed · amber logged only · red missed
Plan for this patient
accepted, measuringrequiredowner · Study nursereview day 113Human Model →
Next action
GI-04 GI Support Protocol
92% probability of improvement
Kept if

91% of 284 similar trajectories improved after GI-04; if this one does, discontinuation risk is expected to fall from 80% to ~50%. Keeping simple carbs low is worth 3.5 GI points a day on its own. Losing this patient costs €6k; the intervention costs €45.

Daily to-dos in the companion
  • 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • 💊Take the dose at the same time relative to your evening meal
  • 💊Electrolyte solution, one sachet after any loose stool
Adherence
69% worsening

Partial adherence; to-dos are being skipped on symptomatic days.

Changes the plan if

GI burden above 60 for 3 days within the onset window

LLIFE OS insight
grounded · add an LLM key for prose

P-02634 is on day 105 of META-24 (EC-03, baseline S14): response favorable, tolerance deteriorating, GI stable. Over 14 days response moved -1 and GI -3; discontinuation risk is 80%. The state is between basins, heading towards restoration, after diverging from the model on day 71.

Biology sets the gain: FUT2 non-secretor, IL6 high-expression variant, Low microbial diversity, Baseline state S14, Cluster EC-03 (high response / high intolerance); butyrate capacity 45/100, diversity 2.4. Pushing it down: Escherichia coli 33.687% (LPS load) (-33.3), 6 keystone species absent (-19.6), FUT2 non-secretor (-15.9). Pulling it up: Dietary Support Protocol NP-02 (+30.8), Butyrate producers intact (+11.2). From the daily log: simple carbs +3.5 GI next day, ultra-processed +3.1 GI next day, protein -2.8 GI next day.

Past actions: NP-02 on day 48 → improved (19%); ME-01 on day 93 → improved (3%).

Next: GI-04 — 91% of 284 similar trajectories improved, 92% probability here. This would be contradicted by a further GI rise within the onset window or falling adherence.

Therapy response
Favorable
Tolerance
Deteriorating
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
80%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (daily oral dose, morning)
  1. Day 0 META-24 startedBaseline state S14
  2. Day 47 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 48 Patient acceptedStarted NP-02 in the companion
  4. Day 58 GI symptom burden −19% vs expectedDietary Support Protocol NP-02
  5. Day 64 Tolerance state changedUnstable → Improving
  6. Day 71 Trajectory diverged from predictionObserved response fell below the model's expected path.
  7. Day 92 ME-01 recommendedMonitoring Escalation ME-01
  8. Day 93 Patient acceptedStarted ME-01 in the companion
  9. Day 96 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 71.

Primary contributors, last 14 days
  • Treatment adherence-16
  • Toxicity+6
  • GI instability-3

What helped?

  • Dietary Support Protocol NP-02Day 47
    Result: symptom burden −19%
  • Monitoring Escalation ME-01Day 92
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04 what is this →
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 91% showed improvement
  • median effect visible after 8 days

Daily trackers

Asset settings

The trackers this program marks as important, last 14 days vs the 14 before.

Glucose, CGM daily mean
CGM
156 mg/dL
worsening · +8.2 vs previous 14 d
Active minutes
Wearable
19 min
worsening · -8.4 vs previous 14 d
Sleep duration
Wearable
5.1 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log
2.6/10
worsening · -1.2 vs previous 14 d
Steps
Wearable
2,171
worsening · -675 vs previous 14 d
GI burden
Companion
51.6/100
worsening · +7.2 vs previous 14 d
Adherence
Companion
69 %
worsening · -15.6 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 43 from the failing basin, 49 from restoration.

Would help
  • GI-04 GI Support Protocol
    73% improved among 60 similar · onset 8 d · confidence 88%
  • SC-12 Supportive Compound
    77% improved among 26 similar · onset 6 d · confidence 71%
  • CR-01 Clinician Review
    100% improved among 12 similar · onset 5 d · confidence 71%
  • More protein
    GI -2.8 next day on high-intake days · n 21
Would not help
  • Keep simple carbs low
    GI +3.5 next day on high-intake days · n 14
  • Keep ultra-processed low
    GI +3.1 next day on high-intake days · n 16
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Simple carbohydrates
    +3.5detractor · 95%
  • Ultra-processed food
    +3.1detractor · 95%
  • Protein
    -2.8supporter · 95%
  • Insoluble fibre
    +1.8no signal · 54%
  • Alcohol
    +0.3no signal · 15%
  • Dietary fat load
    +0.1no signal · 15%

DeepGene damage signature

The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

Damage score · retest day 90
88/100
vs baseline (day 0)
+12
1 improved · 11 worsened
synthetic signature · consistent with this patient's biology
  • 5 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecium
  • 6 keystone species absent
  • Shannon 1.58 (expected ≥ 3)
  • 10 resistance genes
  • Host DNA fragmentation atypical
  • Tissue recycling index 61
Pathogens / opportunists5/5
Keystone species6/8
from 4
Diversity2/2
Metabolic modules1/4
Vitamin synthesis6/7
from 4
Oral translocation1/1
Host DNA1/1
from 0
Tissue recycling1/1
Central mechanisms2/2
from 1
Species dominance1/1
Virulence factors6/6
from 4
Antibiotic resistance genes10/10
from 8
Genetic predisposition2/2
Opportunists above range
Escherichia coli 33.687% AR
Enterococcus faecium 16.843% AR
Klebsiella pneumoniae 10.106% AR
Streptococcus gallolyticus 3.369% AR
Keystone species absent
Akkermansia muciniphila, Bifidobacterium longum, Butyricicoccus pullicaecorum, Eubacterium rectale, Faecalibacterium prausnitzii
Capacity
Shannon 1.58 · butyrate 304 CPM · SCFA 553
H2S above band
6 vitamins below
Host & mechanisms
host DNA fragmentation atypical
tissue recycling 61/100
oral translocation 7.63% AR
molecular_mimicry above
estrobolome above
10 resistance genes · 6 virulence factors

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 90
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 52 and rising
    • WearableSleep 5.1 h, below personal baseline
  • Inflammatory signalling 65
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 55
    • WearableHRV 36 ms, trending down
  • Autonomic recovery 65
    • WearableResting HR 80 bpm
    • Wearable2,171 steps/day
    • WearableShort sleep window
  • Butyrate / short-chain fatty acid production 45
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Drug metabolism and exposure 20
    • BloodToxicity index 54
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
  • GLP1R rs6923761 A
    Altered receptor sensitivity
Microbiome
Shannon diversity 2.4 · butyrate capacity 45/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
38 ms
Sleep
5.6 h
Steps
1,985
Resting HR
78 bpm
Daily log: GI score 52, nutritional resilience 42, adherence 69.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0224451%S05GI-04improved61
P-0250548%S14GI-04improved63
P-0222243%S14GI-04improved63
P-0217842%S14GI-04improved64
P-0263742%S14NP-02improved65
P-0228239%S14GI-04improved59
P-0229139%S14GI-04improved71
P-0227038%S14GI-04improved61
P-0237537%S10CR-01improved68
P-0247237%S14ME-01improved50
P-0230336%S14NP-02improved66
P-0202735%S11CR-01improved62